Ovid Therapeutics Inc. Common Stock
OVIDStock
$2.45+576.63%52W
Market Cap$467.53M
P/E—
Div yield—
Beta0.25
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)30.43%
Price vs S&P 500 (4W)4.91%
VGM Score59.42
Market Capitalization$467.53M
Earnings Surprise History
Q1 26-0.12est. -0.12
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.35
4.35
4.38
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OVIDOvid Therapeutics Inc. Common Stock | C | B | B | $2.45 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Ovid Therapeutics is a biopharmaceutical company developing novel treatments for rare epilepsies and seizure-related neurological disorders. The company's pipeline features multiple programs with potential first-in-class and best-in-class mechanisms of action, targeting patient populations with limited treatment options.